FR2680797A1 - Structure ribozymique derivee de l'arn genomique du virus de l'hepatite delta. - Google Patents
Structure ribozymique derivee de l'arn genomique du virus de l'hepatite delta. Download PDFInfo
- Publication number
- FR2680797A1 FR2680797A1 FR9110872A FR9110872A FR2680797A1 FR 2680797 A1 FR2680797 A1 FR 2680797A1 FR 9110872 A FR9110872 A FR 9110872A FR 9110872 A FR9110872 A FR 9110872A FR 2680797 A1 FR2680797 A1 FR 2680797A1
- Authority
- FR
- France
- Prior art keywords
- ribozymic
- nucleotides
- structure according
- molecule
- rna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091032973 (ribonucleotides)n+m Proteins 0.000 title claims description 30
- 241000724709 Hepatitis delta virus Species 0.000 title claims description 16
- 102000053642 Catalytic RNA Human genes 0.000 title description 26
- 108090000994 Catalytic RNA Proteins 0.000 title description 26
- 108091092562 ribozyme Proteins 0.000 title description 26
- 208000037262 Hepatitis delta Diseases 0.000 title description 2
- 239000012634 fragment Substances 0.000 claims abstract description 30
- 230000000694 effects Effects 0.000 claims abstract description 26
- 238000003776 cleavage reaction Methods 0.000 claims abstract description 22
- 230000007017 scission Effects 0.000 claims abstract description 22
- 230000003197 catalytic effect Effects 0.000 claims abstract description 19
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 13
- 150000007523 nucleic acids Chemical group 0.000 claims abstract description 9
- 239000002773 nucleotide Substances 0.000 claims description 40
- 125000003729 nucleotide group Chemical group 0.000 claims description 38
- 239000000758 substrate Substances 0.000 claims description 14
- 108020004414 DNA Proteins 0.000 claims description 11
- 241001465754 Metazoa Species 0.000 claims description 8
- 230000001225 therapeutic effect Effects 0.000 claims description 5
- 108091033319 polynucleotide Proteins 0.000 claims description 4
- 102000040430 polynucleotide Human genes 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 2
- 238000011321 prophylaxis Methods 0.000 claims 1
- 241000700605 Viruses Species 0.000 abstract description 7
- 210000003705 ribosome Anatomy 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 description 8
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
- 238000012217 deletion Methods 0.000 description 5
- 230000037430 deletion Effects 0.000 description 5
- 229920002401 polyacrylamide Polymers 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 2
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 2
- 101710137500 T7 RNA polymerase Proteins 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 238000000376 autoradiography Methods 0.000 description 2
- 241001493065 dsRNA viruses Species 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 208000005331 Hepatitis D Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000004167 Ribonuclease P Human genes 0.000 description 1
- 108090000621 Ribonuclease P Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 108020004487 Satellite DNA Proteins 0.000 description 1
- 241000251131 Sphyrna Species 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 208000029570 hepatitis D virus infection Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 229940063673 spermidine Drugs 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/123—Hepatitis delta
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3517—Marker; Tag
Landscapes
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Saccharide Compounds (AREA)
Priority Applications (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9110872A FR2680797A1 (fr) | 1991-09-03 | 1991-09-03 | Structure ribozymique derivee de l'arn genomique du virus de l'hepatite delta. |
| AU25583/92A AU669487B2 (en) | 1991-09-03 | 1992-09-03 | Ribosomal structure derived from the genomic RNA structure of the delta hepatitus virus |
| PCT/FR1992/000840 WO1993005157A1 (fr) | 1991-09-03 | 1992-09-03 | Structure ribozymique derivee de l'arn genomique du virus de l'hepatite delta |
| DE69232351T DE69232351T2 (de) | 1991-09-03 | 1992-09-03 | Ribozymstruktur die von den genomischen rns des hepatitis delta virus abgeleitet ist |
| EP92919440A EP0602157B1 (fr) | 1991-09-03 | 1992-09-03 | Structure ribozymique derivee de l'arn genomique du virus de l'hepatite delta |
| JP5505002A JPH06510196A (ja) | 1991-09-03 | 1992-09-03 | 肝炎デルタウイルスのゲノムｒｎａに由来するリボザイム構造 |
| AT92919440T ATE212057T1 (de) | 1991-09-03 | 1992-09-03 | Ribozymstruktur die von den genomischen rns des hepatitis delta virus abgeleitet ist |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9110872A FR2680797A1 (fr) | 1991-09-03 | 1991-09-03 | Structure ribozymique derivee de l'arn genomique du virus de l'hepatite delta. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2680797A1 true FR2680797A1 (fr) | 1993-03-05 |
| FR2680797B1 FR2680797B1 (enExample) | 1995-01-06 |
Family
ID=9416576
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR9110872A Granted FR2680797A1 (fr) | 1991-09-03 | 1991-09-03 | Structure ribozymique derivee de l'arn genomique du virus de l'hepatite delta. |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP0602157B1 (enExample) |
| JP (1) | JPH06510196A (enExample) |
| AT (1) | ATE212057T1 (enExample) |
| AU (1) | AU669487B2 (enExample) |
| DE (1) | DE69232351T2 (enExample) |
| FR (1) | FR2680797A1 (enExample) |
| WO (1) | WO1993005157A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU683011B2 (en) * | 1992-01-13 | 1997-10-30 | Duke University | Enzymatic RNA molecules |
| CA2230203A1 (en) | 1998-04-29 | 1999-10-29 | Universite De Sherbrooke | Delta ribozyme for rna cleavage |
| CN107287352A (zh) * | 2017-08-02 | 2017-10-24 | 山东省农业科学院家禽研究所 | 鸭肠炎病毒和鸭肝炎病毒快速检测的探针引物组及其方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991004324A1 (en) * | 1989-09-25 | 1991-04-04 | Innovir Laboratories, Inc. | Ribozyme compositions and methods for use |
| WO1991004319A1 (en) * | 1989-09-25 | 1991-04-04 | Innovir Laboratories, Inc. | Therapeutic ribozyme compositions and expression vectors |
-
1991
- 1991-09-03 FR FR9110872A patent/FR2680797A1/fr active Granted
-
1992
- 1992-09-03 DE DE69232351T patent/DE69232351T2/de not_active Expired - Fee Related
- 1992-09-03 AT AT92919440T patent/ATE212057T1/de not_active IP Right Cessation
- 1992-09-03 JP JP5505002A patent/JPH06510196A/ja active Pending
- 1992-09-03 WO PCT/FR1992/000840 patent/WO1993005157A1/fr not_active Ceased
- 1992-09-03 AU AU25583/92A patent/AU669487B2/en not_active Ceased
- 1992-09-03 EP EP92919440A patent/EP0602157B1/fr not_active Expired - Lifetime
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991004324A1 (en) * | 1989-09-25 | 1991-04-04 | Innovir Laboratories, Inc. | Ribozyme compositions and methods for use |
| WO1991004319A1 (en) * | 1989-09-25 | 1991-04-04 | Innovir Laboratories, Inc. | Therapeutic ribozyme compositions and expression vectors |
Non-Patent Citations (5)
| Title |
|---|
| JOURNAL OF VIROLOGY vol. 62, no. 12, Décembre 1988, BALTIMORE, US pages 4439 - 4444; KUO, M.Y.-P. ET AL.: 'Characterization of self-cleaving RNA sequences on the genome and antigenome of human hepatitis delta virus' * |
| NATURE. vol. 350, 4 Avril 1991, LONDON GB pages 434 - 436; PERROTTA, A. & BEEN, M.D.: 'A pseudoknot-like structure required for efficient self-cleavage of hepatitis delta virus RNA' * |
| NUCLEIC ACIDS RESEARCH. vol. 18, no. 23, 11 Décembre 1990, ARLINGTON, VIRGINIA US pages 6821 - 6827; PERROTTA, A. & BEEN, M.D.: 'The self-cleaving domain from the genomic RNA of hepatitis delta virus: sequence requirements and the effect of denaturants' * |
| NUCLEIC ACIDS RESEARCH. vol. 19, no. 6, 25 Mars 1991, ARLINGTON, VIRGINIA US pages 1285 - 1289; SMITH, J.B. & DINTER-GOTTLIEB, G.: 'Antigenomic hepatitis delta virus ribozymes self-cleave in 18 M formamide' * |
| PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA. vol. 86, no. 6, Mars 1989, WASHINGTON US pages 1831 - 1835; WU, H.-N. ET AL.: 'Human hepatitis delta virus RNA subfragments contain an autocleavage activity' * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP0602157B1 (fr) | 2002-01-16 |
| EP0602157A1 (fr) | 1994-06-22 |
| AU669487B2 (en) | 1996-06-13 |
| JPH06510196A (ja) | 1994-11-17 |
| WO1993005157A1 (fr) | 1993-03-18 |
| ATE212057T1 (de) | 2002-02-15 |
| AU2558392A (en) | 1993-04-05 |
| DE69232351T2 (de) | 2002-09-26 |
| DE69232351D1 (de) | 2002-02-21 |
| FR2680797B1 (enExample) | 1995-01-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5712128A (en) | Enzymatic RNA molecules | |
| AU2018395054C1 (en) | Unnatural base pair compositions and methods of use | |
| JP7825552B2 (ja) | 非天然ポリペプチドのインビボ合成のための組成物および方法 | |
| US6063566A (en) | Catalytic RNA molecules | |
| WO1995031551A1 (en) | Novel enzymatic rna molecules | |
| DE69125374D1 (en) | Endonukleasen | |
| WO1998002583A9 (en) | Novel catalytic rna molecules | |
| FR3042506A1 (fr) | Outil genetique de transformation de bacteries clostridium | |
| Nelson et al. | Hammerheads derived from sTRSV show enhanced cleavage and ligation rate constants | |
| Côté et al. | Peach latent mosaic viroid is locked by a 2′, 5′-phosphodiester bond produced by in vitro self-ligation | |
| EP0602157B1 (fr) | Structure ribozymique derivee de l'arn genomique du virus de l'hepatite delta | |
| Komtsu et al. | Cross-ligation and exchange reactions catalyzed by hairpin ribozymes | |
| Garcia et al. | Differential RNA-dependent ATPase activities of four rRNA processing yeast DEAD-box proteins | |
| AU708673B2 (en) | Enzymatic RNA molecules | |
| AU704325C (en) | Novel enzymatic RNA molecules | |
| CA3001815C (fr) | Outil genetique de transformation de bacteries clostridium | |
| EP0367637A1 (fr) | Nouveau système eucaryote multifonctionnel in vitro et ses applications | |
| Adams et al. | The Arrangement of genes, their transcription and processing | |
| Lee et al. | Trans-Splicing Ribozymes as Potential HIV Gene Inhibitors | |
| AU4107399A (en) | Novel enzymatic RNA molecules |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| CA | Change of address | ||
| ST | Notification of lapse |
Effective date: 20090529 |